- Home
- ALCE vs TNXP Comparison
ALCE vs TNXP Comparison
Compare ALCE & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALCE
- TNXP
- Stock Information
- Founded
- ALCE 2019
- TNXP 2007
- Country
- ALCE United States
- TNXP United States
- Employees
- ALCE N/A
- TNXP N/A
- Industry
- ALCE Power Generation
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ALCE Utilities
- TNXP Health Care
- Exchange
- ALCE Nasdaq
- TNXP Nasdaq
- Market Cap
- ALCE 3.7M
- TNXP 19.5M
- IPO Year
- ALCE N/A
- TNXP N/A
- Fundamental
- Price
- ALCE $0.84
- TNXP $0.61
- Analyst Decision
- ALCE
- TNXP Strong Buy
- Analyst Count
- ALCE 0
- TNXP 2
- Target Price
- ALCE N/A
- TNXP $53.50
- AVG Volume (30 Days)
- ALCE 99.3K
- TNXP 202.6M
- Earning Date
- ALCE 11-19-2024
- TNXP 11-12-2024
- Dividend Yield
- ALCE N/A
- TNXP N/A
- EPS Growth
- ALCE N/A
- TNXP N/A
- EPS
- ALCE N/A
- TNXP N/A
- Revenue
- ALCE N/A
- TNXP $11,291,000.00
- Revenue This Year
- ALCE N/A
- TNXP $62.53
- Revenue Next Year
- ALCE N/A
- TNXP $26.17
- P/E Ratio
- ALCE N/A
- TNXP N/A
- Revenue Growth
- ALCE N/A
- TNXP 183.05
- 52 Week Low
- ALCE $0.74
- TNXP $0.12
- 52 Week High
- ALCE $140.75
- TNXP $14.08
- Technical
- Relative Strength Index (RSI)
- ALCE 28.33
- TNXP 75.02
- Support Level
- ALCE $0.75
- TNXP $0.32
- Resistance Level
- ALCE $0.84
- TNXP $0.72
- Average True Range (ATR)
- ALCE 0.11
- TNXP 0.15
- MACD
- ALCE 0.03
- TNXP 0.04
- Stochastic Oscillator
- ALCE 19.04
- TNXP 39.61
About ALCE Alternus Clean Energy Inc.
Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.